Blue Horseshoe Stocks: SPY Options Recap & More

SPY Options Update

We were so spot-on with our options alert on the SPY in yesterday’s premarket report, that we feel it necessary to quote our alert verbatim. We stated: “With another reversal appearing likely with this morning’s gap-up in the markets, we’ll want to swing our attention in the opposite direction. The SPY generally trades inversely to the UXVY, thus we’ll be monitoring SPY Weekly $195-197 Calls in the event of a continued uptrend signal.” 

We certainly hope a good number of our readers were able to catch that, as every single one of the contract sets in our targeted range could have facilitated sizable gains on the session. Here’s a breakdown of the possibilities:

$195 Calls  – Daily Range: 2.05-3.50 – Max Gain: 71%
$195.50 Calls  – Daily Range: 1.75-3.15 – Max Gain: 80%
$196 Calls  – Daily Range: 1.48-2.80 – Max Gain: 89%
$196.50 Calls  – Daily Range: 1.25-2.45 – Max Gain: 96%
$197 Calls  – Daily Range: 1.01-2.15 – Max Gain: 113%

In order to take advantage of the SPY moving forward, we’ll need to see a continued boost in stocks. In that event, we may look to roll our strike prices closer to the money, namely the Weekly $198-200.50 Calls.


Apple to Announce iPhone 6S Plus – Options Idea

With Apple officially announcing the release of the iPhone 7 today, which is slated to go on sale at the end of next week, we’re going to want to stay ready for the possibility of an options play to one side or the other. We’ll need to guage public reaction to the new phone; an underwhelming product could result in a PPS decline for AAPL, in which case we’d be monitoring Weekly $112-50-114.50 Puts. In the event of a mainly positive reaction, of course, we’d flip that idea to the Call-side in the same strike price range.


Akebia Therapeutics, Inc. AKBA

AKBA is undergoing a mega gap-up in premarket trading today, largely due to yesterday’s after-hours report of positive Phase II study results. We’ll look to possibly take advantage of the situation; with such a rapid move up, it leaves AKBA open to a dip-and-rip pattern on the chart when sellers come out of the woodwork to take profits off of the table.

We’ve pointed out the previous swing highs as levels at which AKBA will need to maintain support on the dip, in order for us to remain interested:

Akebia Announces Positive Top-Line Results from its Phase 2 Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease (Tue, Sep 8)


Extended Watchlist:
UAPC, CCTC, TPIV, ASTI